In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key ...

The regulatory actions were based on results from the Phase III MATTERHORN trial (NCT04592913), which showed that a ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Silverberg, J.I., Rosmarin, D., Chovatiya, R. et al. The regulatory T cell-selective interleukin-2 receptor agonist ...

Calidi Biotherapeutics, Inc. ('Calidi” or the 'Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...

Creditors navigating the challenges of Subchapter V bankruptcy proceedings must understand their rights, strategies for ...

Flexible spending accounts are offered by employers, and contributions are limited annually (in 2025, the limit is $3,300).

The Food and Drug Administration has granted Fast Track designation to PMN310 for the treatment of Alzheimer disease.

PM EST Webcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section ...

Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

In March 2025, KRRO-110 received orphan drug designation from the U.S. Food and Drug Administration for the treatment of AATD. KRRO-110 is currently being evaluated in the Phase 1/2a REWRITE clinical ...